Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; The First Clinical Medical School of Lanzhou University, Lanzhou, China.
Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China; Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China.
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries.
The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients.
A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models.
Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively.
We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
2019 年冠状病毒病（COVID-19）在中国武汉爆发；该疫情的传播范围比最初估计的要广，目前已在多个国家确认了病例。
本荟萃分析旨在评估严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者合并症的患病率，并比较重症患者与非重症患者潜在疾病的风险。
通过 2020 年 2 月 25 日检索数据库 PubMed、EMBASE 和 Web of Science，进行文献检索。采用随机效应模型汇总比值比（ORs）和 95%置信区间（CIs）。
纳入了 7 项荟萃分析研究，共包括 1576 例感染患者。结果显示，最常见的临床症状是发热（91.3%，95%CI：86-97%），其次是咳嗽（67.7%，95%CI：59-76%）、乏力（51.0%，95%CI：34-68%）和呼吸困难（30.4%，95%CI：21-40%）。最常见的合并症是高血压（21.1%，95%CI：13.0-27.2%）和糖尿病（9.7%，95%CI：7.2-12.2%），其次是心血管疾病（8.4%，95%CI：3.8-13.8%）和呼吸系统疾病（1.5%，95%CI：0.9-2.1%）。与非重症患者相比，重症患者的高血压、呼吸系统疾病和心血管疾病的汇总 OR 分别为 2.36（95%CI：1.46-3.83）、2.46（95%CI：1.76-3.44）和 3.42（95%CI：1.88-6.22）。
我们评估了 COVID-19 患者合并症的患病率，发现高血压、呼吸系统疾病和心血管疾病等基础疾病可能是重症患者与非重症患者相比的危险因素。
